Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience.
John Andrew Livingston
No relevant relationships to disclose
Kenneth R. Hess
No relevant relationships to disclose
Joanna Grace Fernandez
No relevant relationships to disclose
Aung Naing
No relevant relationships to disclose
David S. Hong
No relevant relationships to disclose
Shreyaskumar Patel
Consultant or Advisory Role - GlaxoSmithKline; Johnson & Johnson; Novartis
Research Funding - Eisai; Infinity Pharmaceuticals; Johnson & Johnson; PharmaMar
Peter Meade Anderson
Employment or Leadership Position - LEvine Childrens Hospital
Consultant or Advisory Role - Bayer
Stock Ownership - Helios Products
Honoraria - Bayer
Research Funding - Takeda
Other Remuneration - University of Texas MD Anderson Cancer Center
Robert S. Benjamin
No relevant relationships to disclose
Joseph A. Ludwig
No relevant relationships to disclose
Cynthia E. Herzog
No relevant relationships to disclose
Siqing Fu
No relevant relationships to disclose
Jennifer J. Wheler
No relevant relationships to disclose
Gerald Steven Falchook
No relevant relationships to disclose
Apostolia Maria Tsimberidou
No relevant relationships to disclose
Sarina Anne Piha-Paul
No relevant relationships to disclose
Filip Janku
No relevant relationships to disclose
Eric Rohren
No relevant relationships to disclose
Funda Meric-Bernstam
No relevant relationships to disclose
Razelle Kurzrock
No relevant relationships to disclose
Vivek Subbiah
Research Funding - Bayer; GlaxoSmithKline; NanoCarrier; Northwest Biotherapeutics; Roche/Genentech